S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

AzurRx BioPharma Stock Forecast, Price & News

+0.03 (+2.54 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $1.21
50-Day Range
MA: $1.52
52-Week Range
Now: $1.21
Volume1.86 million shs
Average Volume11.15 million shs
Market Capitalization$91.42 million
P/E RatioN/A
Dividend YieldN/A
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida with scientific operations in Langlade, France and clinical operations in Hayward, California.
AzurRx BioPharma logo


AzurRx BioPharma Announces $8.0 Million Offerings
January 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AZRX
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$0.17 per share


Net Income$-15,180,000.00


Market Cap$91.42 million
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.39 out of 5 stars

Medical Sector

635th out of 1,972 stocks

Pharmaceutical Preparations Industry

297th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+0.03 (+2.54 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

Is AzurRx BioPharma a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AzurRx BioPharma stock.
View analyst ratings for AzurRx BioPharma
or view top-rated stocks.

What stocks does MarketBeat like better than AzurRx BioPharma?

Wall Street analysts have given AzurRx BioPharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AzurRx BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AzurRx BioPharma?

AzurRx BioPharma saw a increase in short interest in January. As of January 29th, there was short interest totaling 2,530,000 shares, an increase of 169.8% from the January 14th total of 937,900 shares. Based on an average daily trading volume, of 6,870,000 shares, the short-interest ratio is currently 0.4 days.
View AzurRx BioPharma's Short Interest

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for AzurRx BioPharma

How has AzurRx BioPharma's stock price been impacted by Coronavirus (COVID-19)?

AzurRx BioPharma's stock was trading at $0.6150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AZRX shares have increased by 96.7% and is now trading at $1.21.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AZRX?

3 brokerages have issued 1 year target prices for AzurRx BioPharma's shares. Their forecasts range from $3.00 to $3.50. On average, they anticipate AzurRx BioPharma's stock price to reach $3.25 in the next year. This suggests a possible upside of 168.6% from the stock's current price.
View analysts' price targets for AzurRx BioPharma
or view top-rated stocks among Wall Street analysts.

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the following people:
  • Mr. James R. Sapirstein R.Ph., M.B.A., CEO, Pres & Non-Independent Director (Age 60, Pay $622k)
  • Mr. Daniel H. Schneiderman, Chief Financial Officer (Age 43, Pay $356.03k)
  • Dr. James E. Pennington, Chief Medical Officer (Age 78, Pay $324.8k)
  • Mr. Martin Krusin M.B.A., Sr. VP of Corp. Devel.

Who are some of AzurRx BioPharma's key competitors?

What other stocks do shareholders of AzurRx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

Who are AzurRx BioPharma's major shareholders?

AzurRx BioPharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.23%), Renaissance Technologies LLC (0.25%) and Parsons Capital Management Inc. RI (0.48%).
View institutional ownership trends for AzurRx BioPharma

Which institutional investors are selling AzurRx BioPharma stock?

AZRX stock was sold by a variety of institutional investors in the last quarter, including Parsons Capital Management Inc. RI.
View insider buying and selling activity for AzurRx BioPharma
or view top insider-selling stocks.

Which institutional investors are buying AzurRx BioPharma stock?

AZRX stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, and Renaissance Technologies LLC.
View insider buying and selling activity for AzurRx BioPharma
or or view top insider-buying stocks.

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $1.21.

How much money does AzurRx BioPharma make?

AzurRx BioPharma has a market capitalization of $91.42 million.

How many employees does AzurRx BioPharma have?

AzurRx BioPharma employs 10 workers across the globe.

What is AzurRx BioPharma's official website?

The official website for AzurRx BioPharma is www.azurrx.com.

Where are AzurRx BioPharma's headquarters?

AzurRx BioPharma is headquartered at 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.